{
    "clinical_study": {
        "@rank": "80475", 
        "arm_group": {
            "arm_group_label": "Arm 1 - GEH120714 (18F) Injection", 
            "arm_group_type": "Experimental", 
            "description": "Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration)."
        }, 
        "brief_summary": {
            "textblock": "To evaluate the safety, bio-distribution, and radiation dosimetry; and to optimize the\n      Imaging Protocol of GEH120714 (18F) Injection.  Study recruits healthy volunteers and\n      participants with relapsing and remitting multiple sclerosis."
        }, 
        "brief_title": "Assess Safety, Bio-distribution, Dosimetry, and Optimize Imaging Protocol of GEH120714 (18F) Injection, in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS)", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Evaluate the Safety of GEH120714 (18F) Injection in Healthy Volunteers (HV) and Participants With rrMS.", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Inclusion Criteria for all Participants:\n\n          -  The subject has a clinically normal or acceptable medical history and physical\n             examination at screening.\n\n          -  The subject has an acceptable kidney function (eGFR >60 mL/min/1.73m2) for\n             administration of Gadolinium.\n\n          -  The subject has a trans-locator protein (TSPO) platelet assay conducted / genotype\n             screen within the past 3 months and is a high or mixed affinity GE-180 binder.\n\n        Inclusion criteria specific for healthy volunteers:\n\n          -  The subject has no clinical history or signs of neurological impairment.\n\n          -  The subject has a normal MRI without central white matter lesions.\n\n        Inclusion criteria specific for participants with relapsing and remitting multiple\n        sclerosis (rrMS):\n\n          -  The subject meets McDonald criteria for relapsing remitting multiple sclerosis.\n\n          -  The subject at screening has at least two central white matter plaques evident on\n             MRI.\n\n          -  The subject at screening has a MRI scan of sufficient quality for Volume of Interest\n             (VOI) definition and co-alignment with Positron Emission Tomography (PET).\n\n        Exclusion Criteria:\n\n        General Exclusion Criteria for all participants:\n\n          -  The subject has a contraindication for Magnetic Resonance Imaging (MRI).\n\n          -  The subject has known allergies to Gadolinium contrast agent.\n\n          -  The subject has received significant ionising radiation exposure from clinical trials\n             or medical examinations in the last 12 months.\n\n        Exclusion Criteria specific for healthy volunteers:\n\n          -  The subject has family history of multiple sclerosis (MS).\n\n          -  The subject is undergoing monitoring of occupational ionising radiation exposure.\n\n        Exclusion Criteria specific for participants with remitting multiple sclerosis (rrMS):\n\n          -  The subject has a past history of cerebrovascular disease or vasculitis.\n\n          -  The subject has a history of head injury with prolonged coma."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01738347", 
            "org_study_id": "GE-180-001"
        }, 
        "intervention": {
            "arm_group_label": "Arm 1 - GEH120714 (18F) Injection", 
            "description": "Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).", 
            "intervention_name": "Arm 1 - GEH120714 (18F) Injection", 
            "intervention_type": "Drug", 
            "other_name": "GEH120714 (18F)"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 20, 2013", 
        "location": {
            "contact": {
                "email": "abesanger@imagingprobes.ca", 
                "last_name": "Angela Besanger", 
                "phone": "905-525-9140"
            }, 
            "contact_backup": {
                "email": "goodbody@imagingprobes.ca", 
                "last_name": "Anne Goodbody", 
                "phone": "905-525-9140"
            }, 
            "facility": {
                "address": {
                    "city": "Princeton", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "08540"
                }, 
                "name": "GE Healthcare"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-label, Non-randomized Study to Assess Safety, Bio-distribution, and Radiation Dosimetry, and Optimize the Imaging Protocol of GEH120714 (18F) Injection, a Marker of Microglial Activation, in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS)", 
        "overall_contact": {
            "email": "abesanger@imagingprobes.ca", 
            "last_name": "Angela Besanger", 
            "phone": "905-525-9140", 
            "phone_ext": "21357"
        }, 
        "overall_official": {
            "affiliation": "GE Healthcare", 
            "last_name": "Paul Sherwin, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Record the occurrence of adverse events (AEs) to evaluate the safety of a single dose of GEH120714 (18F) Injection in healthy volunteers (HV) and participants with rrMS.", 
            "measure": "Record the occurrence of adverse events (AEs) to evaluate the safety of a single dose of GEH120714 (18F) Injection", 
            "safety_issue": "Yes", 
            "time_frame": "Time zero equals the date of contrast imaging and for up to 24 hours for safety monitoring post contrast administration."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01738347"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Collect blood samples at 30 and 120 minutes post drug injection to count radioactivity to determine the bio-distribution, internal radiation dosimetry and Effective Dose (E) of [18F]GEH120714 following intravenous (iv.) administration in healthy volunteers (HVs).", 
                "measure": "Collect blood samples to count radioactivity levels to determine the bio-distribution, internal radiation dosimetry and Effective Dose.", 
                "safety_issue": "No", 
                "time_frame": "Blood samples taken at 30 and 120 minutes post the drug injection."
            }, 
            {
                "description": "Collect urine samples at 90, 180 and 300 minutes post drug injection to count radioactivity to determine the bio-distribution, internal radiation dosimetry and Effective Dose (E) of [18F]GEH120714 following intravenous (iv.) administration in healthy volunteers (HVs).", 
                "measure": "Collect urine samples to count radioactivity levels to determine the bio-distribution, internal radiation dosimetry and Effective Dose.", 
                "safety_issue": "No", 
                "time_frame": "Urine samples taken at 90, 180 and 300 minutes post the drug injection."
            }
        ], 
        "source": "GE Healthcare", 
        "sponsors": {
            "collaborator": {
                "agency": "Centre for Probe Development and Commercialization", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "GE Healthcare", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}